Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:University_of_Arizona_Cancer_Center
gptkb:Sprycel |
| gptkbp:age |
middle-aged adults
|
| gptkbp:associated_with |
gptkb:Philadelphia_chromosome
chronic health conditions psychosocial issues chronic phase symptoms accelerated phase symptoms blast phase symptoms |
| gptkbp:caused_by |
gptkb:BCR-ABL_fusion_gene
|
| gptkbp:clinical_trial |
ongoing research for new therapies
|
| gptkbp:complications |
gptkb:fandom
infections thrombocytopenia blast crisis |
| gptkbp:end_of_life |
70-90% 5-year survival rate with treatment
|
| gptkbp:first_described_by |
1960s
|
| gptkbp:genetic_diversity |
AB L1 gene mutation
BCR gene mutation |
| gptkbp:historical_significance |
first cancer treated with targeted therapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chronic Myeloid Leukemia
|
| gptkbp:is_monitored_by |
cytogenetic analysis
PCR testing |
| gptkbp:is_popular_in |
more common in adults
|
| gptkbp:occurs_in |
1-2 cases per 100,000 people
|
| gptkbp:research_focus |
gptkb:physicist
gptkb:vaccine targeted therapies |
| gptkbp:risk_factor |
age
family history exposure to radiation |
| gptkbp:scientific_classification |
accelerated phase
blast phase chronic phase |
| gptkbp:social_responsibility |
blood test
bone marrow biopsy |
| gptkbp:symptoms |
fatigue
weight loss fever night sweats bleeding gums bone pain easy bruising splenomegaly |
| gptkbp:treatment |
gptkb:Dasatinib
gptkb:Imatinib gptkb:Nilotinib prevent complications Tyrosine kinase inhibitors chemotherapy reduce symptoms stem cell transplant achieve remission |